Stay updated with breaking news from Fatigue Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval.
The approval was based on data from the phase 3 ALPHA trial, which evaluated danicopan as add-on therapy to ravulizumab or eculizumab in adults with PNH and clinically significant EVH.
Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is...
Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of...
Agios Pharmaceuticals Inc.’s stock soared 19.6% early Wednesday, after the biotech announced positive results from a Phase 3 trial of a treatment for a rare...